Anti-GD2 monoclonal antibody immunotherapy: A promising strategy in the prevention of neuroblastoma relapse

Cancer Letters

Volumn 197, Issue 1-2, 2003, Pages 205-209

  Raffaghello, L ^a   Marimpietri, D ^a   Pagnan, G ^a   Pastorino, F ^a   Cosimo, E ^a   Brignole, C ^a   Ponzoni, M ^a   Montaldo, P G ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

Anti GD2; Antibody; Cytotoxicity; Disialoganglioside 2; HTLA 230; Immunotherapy; Minimal residual disease; Monoclonal antibody; Neuroblastoma; Therapy

Indexed keywords

DISIALOGANGLIOSIDE GD2 MONOCLONAL ANTIBODY; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER SURVIVAL; CAUSE OF DEATH; COMPLEMENT DEPENDENT CYTOTOXICITY; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFECT; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VIVO STUDY; LOW DRUG DOSE; MACROPHAGE; METASTASIS; MOUSE; NEUROBLASTOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR RECURRENCE; TUMOR XENOGRAFT;

ANIMALIA; MUS MUSCULUS;

EID: 0012430506     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00100-9     Document Type: Conference Paper

References (10)

1. Seeger R.C., Reynolds C.P. Neoplasms in children: neuroblastoma. Holland J.F., Frei E., Bast R.C., Kufe D.W., Morton D.L., Weichselbaum R.R. Cancer Medicine. 1993;2172-2184 Lea & Febiger, Philadelphia, PA.
2. Schulz G., Cheresh D.A., Varki N.M., Yu A., Staffileno L.K., Reisfeld R.A. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 44:1984;5914-5920.
3. Mujoo K., Cheresh D.A., Yang H.M., Reisfeld R.A. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 4:1987;1098-1104.
4. Bogenmann E. A metastatic neuroblastoma model in SCID mice. Int. J. Cancer. 67:1996;379-385.
5. Murray J.L., Cunningham J.E., Brewer H., Mujoo K., Zukiwski A.A., Podoloff D.A., Kasi L.P., Bhadkamkar V., Fritsche H.A., Benjamin R.S., Legha S.S., Ater J.L., Jaffe N., Itoh K., Ross M.I., Bucana C.D., Thompson L., Cheung L., Rosenblum M.G. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J. Clin. Oncol. 12:1994;184-193.
6. Yu A.L., Uttenreiìuther-Fischer M., Huang C.-S., Tsui C.C., Gillies S.D., Reisfeld R.A., Kung F.H. Phase I trail of human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J. Clin. Oncol. 16:1998;2169-2180.
7. Mujoo K., Kipps T.J., Yang M., Cheresh D.A., Wargalla U., Sandler D., Reisfeld R.A. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res. 49:1989;2857-2861.
8. Moss T.Y., Reynolds C.P., Sather H.N., Romansky S.G., Hammond G.D., Seeger R.C. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N. Engl. J. Med. 324:1991;219-226.
9. Chen S., Caragine T., Cheung N.-K.V., Tomlinson S. Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones. Am. J. Pathol. 156:2000;1085-1091.
10. Tschaikowsky K., Brain J.D. Effects of liposome-encapsulated dichloromethylene diphosphonate on macrophage function and endotoxin-induced mortality. Biochim. Biophys. Acta. 1222:1994;323-330.